Expertise in
15
conditions

Dr. Linda R. Duska

Obstetrics and Gynecology
UVA Health General Gynecology
1221 Lee St Fl 3, 
Charlottesville, VA 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Expertise in
15
conditions
UVA Health General Gynecology
1221 Lee St Fl 3, 
Charlottesville, VA 

Overview

Linda Duska is an Obstetrics and Gynecologist practicing medicine in Charlottesville, Virginia.

Dr. Duska is highly rated in 15 conditions, according to our data. Her clinical expertise encompasses Endometrial Cancer, Ovarian Cancer, Cervical Cancer, Hysterectomy, and Salpingo-Oophorectomy.

She is actively involved in clinical research, co-authoring 135 peer reviewed articles and participating in 34 clinical trials. Dr. Duska is currently accepting new patients.

Specialties

Obstetrics and Gynecology

Licenses

Obstetrics & Gynecology in MA

Hospital Affiliations

University Of Virginia Medical Center

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
HealthKeepers
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Piedmont
  • HMO
  • POS
Sentara Healthcare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

UVA Health General Gynecology
1221 Lee St Fl 3, Charlottesville, VA 22903
Other Locations
UVA Health Gynecologic Oncology
1240 Lee St Fl 2, Charlottesville, VA 22908

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

33 Clinical Trials

A Phase 1/2 Study of DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
A Phase 1/2 Study of DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Enrollment Status: Recruiting
Publish Date: August 19, 2026
Intervention Type: Drug
Study Drugs: CPI-0209, Irinotecan
Study Phase: Phase 1/Phase 2
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Atezolizumab, Bevacizumab, Pegylated liposomal doxorubicin hydrochloride
Study Phase: Phase 2/Phase 3
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: August 25, 2026
Intervention Type: Biological
Study Drug: Dostarlimab
Study Phase: Phase 1
A Randomized Phase 2 Study of Cabozantinib in Combination With Nivolumab in Advanced, Recurrent Metastatic Endometrial Cancer
A Randomized Phase 2 Study of Cabozantinib in Combination With Nivolumab in Advanced, Recurrent Metastatic Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 18, 2026
Intervention Type: Procedure, Drug, Biological
Study Drugs: Cabozantinib S-malate, Nivolumab
Study Phase: Phase 2
Phase 2 Study of M6620 (VX-970) in Combination With Gemcitabine Versus Gemcitabine Alone in Subjects With Platinum-Resistant Recurrent Ovarian or Primary Peritoneal Fallopian Tube Cancer
Phase 2 Study of M6620 (VX-970) in Combination With Gemcitabine Versus Gemcitabine Alone in Subjects With Platinum-Resistant Recurrent Ovarian or Primary Peritoneal Fallopian Tube Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 06, 2026
Intervention Type: Drug
Study Phase: Phase 2
Phase 1 Dose Escalation and Expansion Cohort of Carboplatin and Gemcitabine With or Without M6620 (VX-970) in First or Second Recurrence Platinum-Sensitive Epithelial Ovarian, Peritoneal, and Fallopian Tube Cancer
Phase 1 Dose Escalation and Expansion Cohort of Carboplatin and Gemcitabine With or Without M6620 (VX-970) in First or Second Recurrence Platinum-Sensitive Epithelial Ovarian, Peritoneal, and Fallopian Tube Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Drug, Other
Study Drugs: Berzosertib, Carboplatin, Gemcitabine
Study Phase: Phase 1
Phase I Dose-Escalation Bioavailability Study of Oral Triapine in Combination With Concurrent Chemoradiation for Locally Advanced Cervical Cancer (LACC) and Vaginal Cancer
Phase I Dose-Escalation Bioavailability Study of Oral Triapine in Combination With Concurrent Chemoradiation for Locally Advanced Cervical Cancer (LACC) and Vaginal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Procedure, Drug, Radiation, Other
Study Drugs: Cisplatin, Triapine
Study Phase: Phase 1
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Other, Drug, Procedure, Biological
Study Drugs: Carboplatin, Paclitaxel, Pembrolizumab
Study Phase: Phase 3
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Drug, Procedure, Other
Study Drugs: Carboplatin, Cediranib Maleate, Gemcitabine, Gemcitabine Hydrochloride, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride
Study Phase: Phase 3
A Phase I/Ib Dose Escalation Study of Pegylated Liposomal Doxorubicin (PLD) With Peposertib (M3814) in Platinum - Resistant or Ineligible Ovarian and Related Cancers With Planned Expansions in High Grade Serous (HGSOC) and Low Grade Serous Ovarian Cancer (LGSOC)
A Phase I/Ib Dose Escalation Study of Pegylated Liposomal Doxorubicin (PLD) With Peposertib (M3814) in Platinum - Resistant or Ineligible Ovarian and Related Cancers With Planned Expansions in High Grade Serous (HGSOC) and Low Grade Serous Ovarian Cancer (LGSOC)
Enrollment Status: Active_not_recruiting
Publish Date: July 20, 2026
Intervention Type: Drug, Procedure
Study Drugs: Pegylated Liposomal Doxorubicin Hydrochloride, Peposertib
Study Phase: Phase 1
View 9 Less Clinical Trials

135 Total Publications

Update on immune checkpoint inhibition for cervical cancer.
Update on immune checkpoint inhibition for cervical cancer.
Journal: Clinical advances in hematology & oncology : H&O
Published: May 07, 2026
Similar Doctors
Expertise in
16
conditions
Dr. Paola A. Gehrig
Obstetrics and Gynecology
Expertise in
16
conditions
Dr. Paola A. Gehrig
Obstetrics and Gynecology
Referral may be required

UVA Health Gynecologic Oncology

1240 Lee St Fl 2, 
Charlottesville, VA 
 (6.6 miles away)
434-924-5100
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Paola Gehrig is an Obstetrics and Gynecologist practicing medicine in Charlottesville, Virginia. Dr. Gehrig is highly rated in 16 conditions, according to our data. Her clinical expertise encompasses Endometrial Cancer, Ovarian Cancer, Cervical Cancer, Hysterectomy, and Vaginectomy. Dr. Gehrig is currently accepting new patients.

Expertise in
19
conditions
Dr. Kari L. Ring
Obstetrics and Gynecology
Expertise in
19
conditions
Dr. Kari L. Ring
Obstetrics and Gynecology
Referral may be required

UVA Health Gynecologic Oncology

1240 Lee St Fl 2, 
Charlottesville, VA 
 (6.6 miles away)
434-924-5100
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Kari Ring is an Obstetrics and Gynecologist practicing medicine in Charlottesville, Virginia. Dr. Ring is highly rated in 19 conditions, according to our data. Her clinical expertise encompasses Endometrial Cancer, Ovarian Cancer, Li-Fraumeni Syndrome, Salpingo-Oophorectomy, and Hysterectomy. Dr. Ring is currently accepting new patients.

Expertise in
15
conditions
Dr. Marilyn S. Huang
Obstetrics and Gynecology
Expertise in
15
conditions
Dr. Marilyn S. Huang
Obstetrics and Gynecology
Referral may be required

UVA Health General Gynecology

1221 Lee St Fl 3, 
Charlottesville, VA 
 (0.1 miles away)
434-924-1955
Languages Spoken:
English, Mandarin
See accepted insurances
Accepting New Patients
Offers Telehealth

Marilyn Huang is an Obstetrics and Gynecologist practicing medicine in Charlottesville, Virginia. Dr. Huang is highly rated in 15 conditions, according to our data. Her clinical expertise encompasses Cervical Cancer, Ovarian Cancer, Endometrial Cancer, Vulvar Cancer, and Hysterectomy. Dr. Huang is currently accepting new patients.

Frequently Asked Questions about Dr. Linda R. Duska

How do I make an appointment with Dr. Linda R. Duska?

You can book an appointment with Dr. Linda R. Duska by calling their office at 434-924-1955. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Linda R. Duska a top-rated expert for Endometrial Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Linda R. Duska is classified as an Elite expert for Endometrial Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Linda R. Duska specialize in?

While Dr. Linda R. Duska is a Obstetrics and Gynecology, they have specific expertise in Endometrial Cancer, Ovarian Cancer, and Cervical Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Obstetrics and Gynecology.

Does Dr. Linda R. Duska participate in research or clinical trials?

Yes. Dr. Linda R. Duska has published 135 articles and abstracts on conditions like Endometrial Cancer. You can view a list of Dr. Linda R. Duska's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Linda R. Duska accept my insurance?

Dr. Linda R. Duska accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 434-924-1955 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Duska's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 30 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile